PN vs PDRN vs Exosomes: A UK Practitioner Guide

Evidence reviewed: September 2026. PN, PDRN and exosomes are increasingly grouped together under “regenerative aesthetics”, but they are not interchangeable materials. They differ in composition, proposed mechanisms, evidence maturity, regulation and—critically—the route by which a particular product is intended to be used.

Quick answer: PN describes longer-chain polynucleotides used in a growing range of injectable biostimulatory products. PDRN is a more specific mixture of lower-molecular-weight DNA fragments with a substantial research history in tissue repair and wound healing. Exosomes are nanoscale extracellular vesicles involved in cell-to-cell signalling; aesthetic products marketed as “exosome” treatments are a different and far less standardised category. A product containing one should never be assumed equivalent to another simply because all three are marketed as regenerative.

PN vs PDRN vs exosomes at a glance

What are polynucleotides (PN)?

Polynucleotides are chains of nucleotides—the structural units of DNA. In aesthetic medicine, purified PN formulations are used as injectable products intended to improve tissue quality rather than create conventional filler-like projection.

Products within the category are not identical. Molecular weight, concentration, purification, viscosity and intended anatomical area can vary. Longeva currently stocks PN ranges including VITARAN II, Nucleofill Strong Plus, PLINEST and dedicated periocular options.

For practitioners wanting the wider category explained in depth, see Polynucleotides: What Practitioners Should Understand and our under-eye PN comparison.

What is PDRN?

PDRN stands for polydeoxyribonucleotide. It consists of purified DNA fragments and has been studied in regenerative medicine for tissue repair, angiogenesis and wound-healing contexts. Proposed biological effects in the literature include adenosine A2A-receptor signalling and provision of nucleotides through salvage pathways.

The terminology becomes confusing because commercial aesthetic copy sometimes uses “PN” and “PDRN” as though they are synonyms. They are related DNA-derived materials, but practitioners should not automatically treat the terms—or products carrying them—as clinically interchangeable.

PN vs PDRN: what is the practical difference?

The most useful practitioner distinction is not simply “long DNA versus short DNA”. It is to ask what is actually in the syringe or vial, how it has been manufactured, what molecular characteristics and concentration the manufacturer specifies, what route is authorised or intended, and what evidence exists for that exact formulation.

This matters because a claim demonstrated with one PDRN preparation cannot automatically validate every PN injectable—and evidence from one branded PN product cannot automatically be transferred to another.

What are exosomes?

Exosomes are small extracellular vesicles released by cells. They can carry proteins, lipids and nucleic acids and participate in intercellular signalling. Their biological interest is genuine, but “exosome” is not a single standardised cosmetic ingredient.

The source cell, isolation method, purification, vesicle characterisation, storage and final formulation can materially affect what an exosome preparation contains. That makes product-level scrutiny especially important.

Are exosomes proven for skin rejuvenation?

The scientific literature is promising, but it is substantially more heterogeneous than the marketing category suggests. A 2026 systematic review of human extracellular-vesicle/exosome skin-rejuvenation studies found signals of improvement in measures such as wrinkles, pigmentation, hydration and elasticity, but protocols, sources, preparation methods and outcome measures varied considerably.

That creates an important evidence boundary: a positive study involving one extracellular-vesicle preparation does not validate every commercial product marketed with the word “exosome”. Practitioners should distinguish biological plausibility, early clinical evidence and product-specific proof.

Can exosomes be injected?

This is where route and regulatory status become crucial. A product marketed for topical or post-procedure application should not be injected merely because its ingredients sound regenerative. Practitioners must use the product only within its documented intended route and applicable regulatory framework.

Longeva's active ReversHA Exosomes Skin Booster 5 x 5 mL listing combines milk-derived exosome material with PDRN, dual-molecular-weight HA, peptides and amino acids. Its presence on a professional aesthetics site does not itself establish an injectable route; practitioners should check the current manufacturer documentation before clinical use.

View ReversHA Exosomes Skin Booster →

Which has the strongest evidence?

There is no defensible universal winner. A 2026 systematic review of randomised PN/PDRN trials identified seven trials involving 183 participants across skin rejuvenation, scar prevention and wound healing. The results support biological and clinical activity, while also showing that the human evidence base is still relatively compact. Exosome/EV studies are expanding, but product source and preparation are much less standardised. The clinically useful question is therefore whether evidence matches the specific material, product, indication, route and patient.

Evidence hierarchy: what should influence a buying decision?

What can PN products add to an aesthetic clinic?

PN injectables can create a distinct treatment category between conventional skin boosters and volumising fillers. They are particularly relevant when consultation goals centre on tissue quality rather than projection.

Current Longeva options include:

• VITARAN II 2 mL — active PN injectable for face, neck, hands and décolletage.
• VITARAN I 1 mL — periocular-focused presentation.
• Nucleofill Strong Plus 2.5% 2 mL — higher-concentration PN formulation.
• Nucleofill Soft Plus Eyes 0.75% 2 mL — dedicated periocular formulation.
• PLINEST 2 mL — Mastelli PN product.

Where does PDRN fit commercially?

PDRN is increasingly visible in professional skin-rejuvenation formulations, including combination products. Clinics should resist choosing products simply because “PDRN” is prominent on the label. Concentration, other ingredients, intended route and supporting evidence are more useful purchasing criteria.

Longeva also has PURI PDRN in its catalogue, but it is currently a draft/out-of-stock product, so it should not form the commercial CTA of this article until availability changes.

Where do exosome products fit?

Exosome-containing formulations may be commercially relevant to clinics offering advanced skin procedures, particularly where the manufacturer's documented route supports post-procedure/topical use. The key is not to convert a topical regenerative concept into an injectable protocol without evidence and appropriate product authorisation.

PN, PDRN or exosomes after microneedling?

Microneedling creates controlled microchannels and temporarily alters barrier function. That does not make every injectable, cosmetic serum or regenerative product automatically suitable for needling into compromised skin.

The practitioner should check sterility, intended route, manufacturer protocol and compatibility with the device/procedure. For a deeper discussion, see What Serum Can You Use With Microneedling?.

How should practitioners compare regenerative products before buying?

1. Identify the material: PN, PDRN, extracellular vesicles/exosomes or a combination formulation.
2. Check the intended route: injectable, intradermal, topical or post-procedure use are not interchangeable.
3. Verify product-specific evidence: do not borrow clinical results from a different formulation.
4. Review regulatory documentation: marketing terminology does not determine legal or clinical status.
5. Assess concentration and presentation: more concentrated does not automatically mean better.
6. Match the patient objective: skin quality, periocular treatment, scalp treatment and post-procedure recovery are different use cases.
7. Consider clinic economics: pack size, wastage, treatment course, repeat demand and existing brand ecosystem all affect stock decisions.

Common PN, PDRN and exosome mistakes

• Using PN and PDRN as automatic synonyms.
• Assuming all products labelled “exosome” contain equivalent vesicles.
• Transferring evidence from one branded product to another.
• Confusing topical suitability with injectable suitability.
• Choosing concentration before defining the clinical objective.
• Repeating manufacturer marketing claims as established clinical facts.

Frequently asked questions

Is PDRN the same as polynucleotides?

No. They are related DNA-derived materials, and terminology is sometimes used loosely in aesthetics, but they should not automatically be treated as identical substances or interchangeable products.

Are salmon DNA and PDRN the same thing?

Some PN and PDRN preparations are derived from purified salmonid DNA, but source alone does not define the finished material. Processing, fragment size, purification and formulation matter.

Are exosomes better than polynucleotides?

There is no evidence-based universal superiority claim. They are fundamentally different biological categories with different evidence bases and product formats.

Can PN and exosomes be used together?

Potentially in a broader treatment plan where the specific products, routes and manufacturer guidance support it. The existence of two regenerative products does not itself justify combining them.

Which category is easiest to introduce into an injectable clinic?

For practitioners already trained in injectable skin-quality treatments, established PN products with clear manufacturer protocols provide a more defined injectable pathway. Exosome products require particularly careful scrutiny of intended route and regulatory documentation.

Why stock regenerative products from Longeva?

A useful regenerative range should give practitioners distinct treatment options rather than duplicate labels. Longeva's active range already spans full-face PN, periocular PN, scalp PN and an exosome/PDRN combination skin-booster product, allowing clinics to build a more coherent regenerative category.

Shop VITARAN II →   |   Shop Nucleofill Strong Plus →   |   Shop PLINEST →   |   View ReversHA Exosomes →

Practitioner takeaway

PN, PDRN and exosomes belong in the same conversation because they are all marketed within regenerative aesthetics—but they should not be collapsed into one category. The clinically stronger approach is to identify the material, verify the exact product and route, examine evidence at product level and then decide whether it genuinely fills a treatment need in the clinic.

That approach is also commercially stronger: practitioners buy products for a defined clinical role rather than accumulating overlapping “regenerative” stock with no clear treatment pathway.

References and further reading

• Comparison of polynucleotide and hyaluronic acid fillers for periocular rejuvenation: randomized, double-blind, split-face trial.
• Polynucleotides and Polydeoxyribonucleotides for Skin Rejuvenation, Postoperative Scar Prevention, and Wound Healing: systematic review of randomized clinical trials (2026).
• Prospective observational study of polynucleotide injections for periorbital rhytides (2026).
• Systematic review of extracellular vesicle/exosome approaches for human skin rejuvenation (2026).

Professional information only. Intended for appropriately qualified healthcare and aesthetic professionals. This article does not replace the current manufacturer IFU, regulatory documentation, hands-on training, patient-specific assessment or complication-management protocols. Product specifications and regulatory positions can change; verify current primary documentation before clinical use.